Literature DB >> 22902667

Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations.

Anke Hemmerling1, William G Harrison, Joelle Morgan Brown, Barbara Moscicki, Maria Oziemkowska, Elizabeth A Bukusi, Craig R Cohen.   

Abstract

Dye staining of applicators has been shown to be a reliable and objective method to test vaginal insertion in clinical microbicide trials, but different plastics, dyes, and product formulations may impact the accuracy of this method. Reportedly used applicators returned from 3 clinical trials were stained with 1% trypan blue. In a phase 1 study (VivaGel), using gel-filled HTI polypropylene applicators, 1271 (97%) of applicators stained positive. In a phase 1 and a phase 2a study (LACTIN-V) using linear low-density polyethylene applicators to deliver a dry powder formulation, 57 (95%) and 135 (86%) tested positive, respectively. Dye staining of vaginal applicators is an objective low-cost measure suitable for low-resource settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902667      PMCID: PMC3726043          DOI: 10.1097/OLQ.0b013e3182641f08

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  14 in total

1.  Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.

Authors:  Anke Hemmerling; William Harrison; Adrienne Schroeder; Jeanna Park; Abner Korn; Stephen Shiboski; Anne Foster-Rosales; Craig R Cohen
Journal:  Sex Transm Dis       Date:  2010-12       Impact factor: 2.830

2.  Assessment of adherence to product dosing in a pilot microbicide study.

Authors:  Kathleen Hogarty; Andrea Kasowitz; Betsy C Herold; Marla J Keller
Journal:  Sex Transm Dis       Date:  2007-12       Impact factor: 2.830

Review 3.  Biomarkers of semen exposure.

Authors:  Christine K Mauck
Journal:  Sex Transm Dis       Date:  2009-03       Impact factor: 2.830

4.  Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators.

Authors:  Lauren L Katzen; José A Fernández-Romero; Avina Sarna; Kailapuri G Murugavel; Daniel Gawarecki; Thomas M Zydowsky; Barbara S Mensch
Journal:  Sex Transm Dis       Date:  2011-11       Impact factor: 2.830

5.  Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews.

Authors:  Abigail Norris Turner; Alana E De Kock; Amy Meehan-Ritter; Kelly Blanchard; Mohlatlego H Sebola; Anwar A Hoosen; Nicol Coetzee; Charlotte Ellertson
Journal:  J Clin Epidemiol       Date:  2008-11-14       Impact factor: 6.437

6.  Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials.

Authors:  Andrea R Wallace; Aaron Teitelbaum; Livia Wan; Maria Gloria Mulima; Laura Guichard; Stephanie Skoler; Stephanie Skiler; Hlengiwe Vilakazi; Fridda S Mapula; Jasmine Rossier; Sumen N Govender; Pekka Lahteenmaki; Robin A Maguire; David M Phillips
Journal:  Contraception       Date:  2007-05-11       Impact factor: 3.375

7.  Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.

Authors:  Anke Hemmerling; William Harrison; Adrienne Schroeder; Jeanna Park; Abner Korn; Stephen Shiboski; Craig R Cohen
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

8.  Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.

Authors:  Nancy S Padian; Ariane van der Straten; Gita Ramjee; Tsungai Chipato; Guy de Bruyn; Kelly Blanchard; Stephen Shiboski; Elizabeth T Montgomery; Heidi Fancher; Helen Cheng; Michael Rosenblum; Mark van der Laan; Nicholas Jewell; James McIntyre
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

9.  Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.

Authors:  Michele N Austin; Lorna K Rabe; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

10.  A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

Authors:  Craig R Cohen; Joelle Brown; Anna-Barbara Moscicki; Elizabeth A Bukusi; Jeremy R A Paull; Clare F Price; Stephen Shiboski
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

View more
  7 in total

Review 1.  Methodological lessons from clinical trials and the future of microbicide research.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Miriam Hartmann; Alexandra Minnis
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

2.  Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.

Authors:  Craig R Cohen; Michael R Wierzbicki; Audrey L French; Sheldon Morris; Sara Newmann; Hilary Reno; Lauri Green; Steve Miller; Jonathan Powell; Thomas Parks; Anke Hemmerling
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

3.  Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies.

Authors:  Wutyi S Aung; Rahul P Bakshi; Jennifer Breakey; James E Johnson; Craig W Hendrix; Ethel Weld; Edward J Fuchs; Mark A Marzinke
Journal:  AIDS Behav       Date:  2019-01

4.  Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex.

Authors:  Marla J Keller; Niall Buckley; Lauren L Katzen; Jennifer Walsh; Barbara Friedland; Sarah Littlefield; Juan Lin; Xiaonan Xue; Terri Cornelison; Betsy C Herold; Mark H Einstein
Journal:  Sex Transm Dis       Date:  2013-12       Impact factor: 2.830

5.  Empowering HIV-infected women in low-resource settings: A pilot study evaluating a patient-centered HIV prevention strategy for reproduction in Kisumu, Kenya.

Authors:  Okeoma Mmeje; Betty Njoroge; Pauline Wekesa; Alfred Murage; Raphael O Ondondo; Sheryl van der Poel; Mary A Guzé; Starley B Shade; Elizabeth A Bukusi; Deborah Cohan; Craig R Cohen
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

6.  Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.

Authors:  Terry A Jacot; Ashley Nelson; Andrea Thurman; Angela D M Kashuba; David F Archer; Gustavo F Doncel
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

7.  Firmness Perception Influences Women's Preferences for Vaginal Suppositories.

Authors:  Toral Zaveri; Rachel J Primrose; Lahari Surapaneni; Gregory R Ziegler; John E Hayes
Journal:  Pharmaceutics       Date:  2014-09-10       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.